The German vaccine manufacturer CureVac is dropping further work on the development of a corona vaccine, as it has long prospects of entering the market.
This is stated in a statement from CureVac.
The vaccine was originally intended to play a role in the Danish vaccine effort. But it was not approved before the summer holidays, as the Danish health authorities had expected.
In June, CureVac presented the results of a Phase 3 trial. It showed an effect of 48 percent in preventing corona disease.
It is significantly lower than the other vaccines approved in Europe. However, it is with the proviso that one cannot compare one to one across studies.
The vaccine from CureVac was one of the seven vaccines that Denmark has put a ticket on.
According to the Danish Medicines Agency, Denmark has an agreement via the EU Commission to be able to buy 9.1 million vaccine doses of CureVac, if it had been approved to enter the market.
However, CureVac states in the announcement that the agreement is no longer valid. This is because it only applied to cover an urgent need for vaccines during the pandemic.
It also affects the decision to stop further work, writes CureVac.
The European Medicines Agency (EMA) has in recent months been looking at study results with the CureVac vaccine.
Based on its ongoing dialogue with the EMA, CureVac estimates that the vaccine could be approved by the end of 2022 at the earliest.
Denmark has agreements with other manufacturers – including Pfizer / BioNTech and Moderna, so there are vaccines to provide more plugs for the population.
CureVac will instead focus on developing another coronavina vaccine. This is done in collaboration with British GlaxoSmithKline.
It is expected to be completed and approved sooner than the end of 2022. CureVac states.
Source: The Nordic Page